Granules India Event Update By Emkay

Tagged: Emkay, Granules India

This topic has 0 replies, 1 voice, and was last updated 8 years, 5 months ago by Vidhi Khanna.

Viewing 1 post (of 1 total)

Author

Posts
June 11, 2016 at 11:04 am #3214

Vidhi Khanna
Keymaster

In-licensing opportunity: In-licensed pipeline consists of two CVS drugs (gMultaq and gEffient) and two CNS drugs (gGilenya and gLatuda). We expect the first ANDA (gLatuda) to be commercialized in the US only as early as July 2018 (FY2019). In-licensed innovator products had combined annual US revenues of ~USD4.4bn as per IMS.

Significant step in scaling up it US footprint: Granules currently has 2 ANDA’s approved in the US, namely Ibuprofen and Metformin HCL. We believe recent developments including the in licensing deals with Par and US pharma Windlas would help the company to expand its product offering and strengthen its customer footprint.

Granules India Event Update_100616
Author

Posts

Viewing 1 post (of 1 total)

You must be logged in to reply to this topic.